Galmed pharmaceuticals provides business updates and reports first quarter 2021 financial results

Tel aviv, israel, may 13, 2021 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted scd1 modulator aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or nash and fibrosis, reports financial results for the three months ended march 31, 2021.
GLMD Ratings Summary
GLMD Quant Ranking